Skip to content

Ardelyx ARDX Operating lease liabilities

Operating lease liabilities at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+75.8%
Enterprise value$1.71B+71.5%
P/S3.6×+1.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%
Net margin-13.6%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-39.5%
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's operating lease liabilities?
Ardelyx (ARDX) reported operating lease liabilities of -$373K in Q1 2026.
How has Ardelyx's operating lease liabilities changed year-over-year?
Ardelyx's operating lease liabilities increased by 62.4% year-over-year, from -$991K to -$373K.
What is the long-term trend for Ardelyx's operating lease liabilities?
Over 4 years (2021 to 2025), Ardelyx's operating lease liabilities has grown at a -10.5% compound annual growth rate (CAGR), from -$2.85M to -$1.83M.